Overview

Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This study investigates the safety and tolerability as well as the efficacy and pharmacokinetics of caspofungin in four escalating dosages in adult patients with hematologic malignancies and proven or probable invasive aspergillosis.
Phase:
Phase 2
Details
Lead Sponsor:
University of Cologne
Treatments:
Caspofungin
Echinocandins